ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,268.05
      -3.46%
      US Tech 100
      17,860.00
      -4.18%
      Dow Jones
      39,593.66
      -2.50%
      Brent Oil
      63.205
      -3.50%
      Bitcoin
      79,448.40
      -3.80%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Prime Medicine Inc (PRME) Quote

      Prime Medicine Inc

      Prime Medicine Inc (PRME)

      Prim SA
      Prim SA
      Prim SA
      Prim SA
      Prime Drink Group Corp
      1.17
      -0.08
      (-6.40%)
      At close: April 10 4:00PM
      Delayed by 15 minutes
      1.17
      0.00
      ( 0.00% )
      After Hours: 7:00PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      1.17
      Bid
      1.16
      Ask
      1.27
      Volume
      1,816,349
      1.13 Day's Range 1.2916
      1.115 52 Week Range 8.27
      Market Cap
      153.458M
      Previous Close
      1.25
      Open
      1.23
      Last Trade
      20
      @
      1.26
      Last Trade Time
      19:00:39
      Financial Volume
      $ 2,115,402
      VWAP
      1.1646
      Average Volume (3m)
      1,284,730
      Shares Outstanding
      131,160,842
      Dividend Yield
      -
      PE Ratio
      -0.78
      Earnings Per Share (EPS)
      -1.49
      Revenue
      2.98M
      Net Profit
      -195.88M

      About Prime Medicine Inc

      Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.primemedicine.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Prime Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PRME. The last closing price for Prime Medicine was $1.25. Over the last year, Prime Medicine shares have traded in a share price range of $ 1.115 to $ 8.27.

      Prime Medicine currently has 131,160,842 shares outstanding. The market capitalization of Prime Medicine is $163.95 million. Prime Medicine has a price to earnings ratio (PE ratio) of -0.78.

      Ask ADVFN Intelligence (AI)

      PRME Latest News

      More News

      Form 8-K - Current report
      Edgar (US Regulatory)
      March 18 2025
      PRME (-6.40%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      March 03 2025
      PRME (-6.40%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      March 03 2025
      PRME (-6.40%)

      Form S-8 - Securities to be offered to employees in employee benefit plans
      Edgar (US Regulatory)
      February 28 2025
      PRME (-6.40%)

      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      Edgar (US Regulatory)
      February 28 2025
      PRME (-6.40%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 28 2025
      PRME (-6.40%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.53-31.17647058821.71.711.11522258491.32999438CS
      4-0.74-38.74345549741.912.29921.11516538091.70685094CS
      12-1.73-59.65517241382.93.361.11512847302.18459833CS
      26-2.33-66.57142857143.54.711.11511923032.80679663CS
      52-4.65-79.89690721655.828.271.11511446483.83226347CS
      156-17.8-93.832366895118.9721.73011.1157107266.34002737CS
      260-17.8-93.832366895118.9721.73011.1157107266.34002737CS

      PRME - Frequently Asked Questions (FAQ)

      What is the current Prime Medicine share price?
      The current share price of Prime Medicine is $ 1.17
      How many Prime Medicine shares are in issue?
      Prime Medicine has 131,160,842 shares in issue
      What is the market cap of Prime Medicine?
      The market capitalisation of Prime Medicine is USD 163.95M
      What is the 1 year trading range for Prime Medicine share price?
      Prime Medicine has traded in the range of $ 1.115 to $ 8.27 during the past year
      What is the PE ratio of Prime Medicine?
      The price to earnings ratio of Prime Medicine is -0.78
      What is the cash to sales ratio of Prime Medicine?
      The cash to sales ratio of Prime Medicine is 51.54
      What is the reporting currency for Prime Medicine?
      Prime Medicine reports financial results in USD
      What is the latest annual turnover for Prime Medicine?
      The latest annual turnover of Prime Medicine is USD 2.98M
      What is the latest annual profit for Prime Medicine?
      The latest annual profit of Prime Medicine is USD -195.88M
      What is the registered address of Prime Medicine?
      The registered address for Prime Medicine is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
      What is the Prime Medicine website address?
      The website address for Prime Medicine is www.primemedicine.com
      Which industry sector does Prime Medicine operate in?
      Prime Medicine operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BGLCBioNexus Gene Lab Corporation
      $ 3.85
      (77.42%)
      		2.46M
      VEROVenus Concept Inc
      $ 6.15
      (51.48%)
      		1.1M
      ONVOOrganovo Holdings Inc
      $ 3.0497
      (39.89%)
      		2.4M
      SDASunCar Technology Group Inc
      $ 3.59
      (36.50%)
      		10.66k
      CERTCertara Inc
      $ 13.14
      (25.02%)
      		661.61k
      NOTVInotiv Inc
      $ 0.9606
      (-31.87%)
      		1.4M
      PEVPhoenix Motor Inc
      $ 0.2966
      (-14.00%)
      		187.73k
      BAOSBaosheng Media Group Holdings Ltd
      $ 2.16
      (-12.55%)
      		3.51k
      WCTWellchange Holdings Company Limited
      $ 0.2491
      (-11.04%)
      		129.31k
      TBHBrag House Holdings Inc
      $ 0.5625
      (-9.27%)
      		77.8k
      DMNDamon Inc
      $ 0.0039
      (-7.14%)
      		264.56M
      STSSSharps Technology Inc
      $ 0.0195
      (6.56%)
      		21.23M
      FMTOFemto Technologies Inc
      $ 0.035
      (-1.96%)
      		14.58M
      SUNESUNation Energy Inc
      $ 0.0225
      (6.13%)
      		13.74M
      LGMKLogicMark Inc
      $ 0.01
      (6.38%)
      		9.05M

      PRME Discussion

      View Posts
      Monksdream Monksdream 4 months ago
      PRME, under $

      👍️0
      PonkenPlonken PonkenPlonken 4 months ago
      Super super undervalued..
      Recent PSTX - Roche deal should have made this run? Atleast given it also recently partnered with BMS... makes zero sense.
      Is a clear validation CRISPR genome editing is hot in cancer cell therapy.
      Waiting for a sign....
      👍️0
      Monksdream Monksdream 6 months ago
      PRME under $5
      👍️0
      Monksdream Monksdream 6 months ago
      PRME new 52 week low
      👍️0
      Invest-in-America Invest-in-America 6 months ago
      PRME: Glad I grabbed a chunk of THIS ONE!!!!
      👍️0
      PonkenPlonken PonkenPlonken 6 months ago
      "Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones,..."

      "On the Effective Date, the Company entered into the Purchase Agreement with BMS, pursuant to which the Company agreed to issue and sell, and BMS agreed to purchase, in an unregistered offering (the “Offering”), 11,006,163 shares [...] for an aggregate purchase price of $55.0 million..."
      👍️0
      Monksdream Monksdream 7 months ago
      PRME new 52=week low
      👍️0
      wiwineguy wiwineguy 7 months ago
      K. I'm in!
      👍️0
      Monksdream Monksdream 7 months ago
      DAKT
      👍️0
      wiwineguy wiwineguy 7 months ago
      You are amazing Monk. Any recommendations
      👍️0
      Monksdream Monksdream 7 months ago
      PRME under $5
      👍️0
      Monksdream Monksdream 8 months ago
      PRME new 52 week low
      👍️0
      Monksdream Monksdream 8 months ago
      PRME under $6
      👍️0
      Monksdream Monksdream 9 months ago
      PRME under $10:
      👍️0
      Monksdream Monksdream 10 months ago
      Great post
      Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
      I think she has been buying on the decline
      She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
      There are about a dozen, if not more, listed gene editing companies
      Not all will make it before they run out of money and have to raise more operating capital
      Notice the $2 to $4 bounces on the way to lower lows
      👍️0
      Monksdream Monksdream 10 months ago
      PRME under $10
      👍️0
      jondoeuk jondoeuk 11 months ago
      PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

      They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
      👍️0
      NY1972 NY1972 12 months ago
      This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
      👍️0
      jondoeuk jondoeuk 12 months ago
      I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
      👍️0
      jondoeuk jondoeuk 1 year ago
      The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
      👍️0

      Your Recent History

      NASDAQ
      PRME
      Prime Medicine
      BIT
      1FB
      Meta Platforms
      BIT
      VIV
      Vivendi
      BIT
      1DR
      Deutsche Rohstoff
      BIT
      CEU
      ETF
      BIT
      BNP
      BNP Paribas
      BIT
      US3
      Amundi Us Treasury 3-7 U...
      NASDAQ
      WPRT
      Westport Fuel Systems
      BIT
      GHC
      Garofalo Health Care
      BIT
      FAE
      FAE Technology
      BIT
      SOU
      Sourcesense
      BIT
      ERG
      ERG
      BIT
      FNL
      Finlogic
      BIT
      PRM
      Primi Sui Motori
      BIT
      DIS
      D Amico International Sh...
      BIT
      SMO
      SIPARIO MOVIES
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads